Anne Cust

PhD, MPH(Hons), BSc, BA

Professor Cust is Deputy Director of the Daffodil Centre, a joint venture between Cancer Council NSW and the University of Sydney. She is also a Faculty member of the Melanoma Institute Australia, affiliated with the University of Sydney. At the Melanoma Institute Australia, she also Chairs the Research Committee and co-leads the ‘Prevention, Risk and Clinical Detection of Melanoma’ research theme. Her position is funded through a National Health and Medical Research Council (NHMRC) Career Development Fellowship.

She is an internationally recognised cancer epidemiologist with expertise in collaborative, multidisciplinary research with a strong emphasis on translational outcomes. Her research predominantly focuses on melanoma prevention and early detection. She leads programs of research on melanoma risk prediction, risk-stratified cancer prevention and screening, and the genetic epidemiology of melanoma. In collaboration with Professor Mann, Professor Cust led the sunbed research that was instrumental in informing government bans on commercial solaria now in effect across all states of Australia, and received an inaugural Sax Institute Research Action Award to recognise this research and translation efforts.

She is the immediate past-President of the Australasian Epidemiological Association and is a member of the Clinical Oncology Society of Australia (COSA) Epidemiology Group Executive. She is actively involved in international melanoma consortia, including the GenoMEL (Genetics of Melanoma) Analysis Team, the GEM (Genes, Environment and Melanoma) Steering group, and the InterMEL (Integration of Clinical and Molecular Biomarkers for Melanoma Survival) Investigator team.

She contributed to the chapter on high-risk individuals for the NHMRC/CCA Clinical Practice Guidelines on Melanoma and has authored chapters for internationally renowned melanoma textbooks.

 

Role

In the Centre of Research Excellence in Melanoma, Professor Cust is the Lead Chief Investigator and co-leader of CRE Core 1: Identifying and managing people at high risk of developing melanoma. She contributes to the work of all Cores.

View Profile
View Website
   

Graham Mann

MBBS, PhD, FRACP

Professor Mann is Director of the John Curtin School of Medical Research, in the College of Health and Medicine, Australian National University.

Research Interests

Professor Mann has an international reputation in the genomics and genetic epidemiology of melanoma, and in translational oncology. Many of his outputs arise from highly productive research consortia and multidisciplinary and inter-disciplinary partnerships. He is co-PI of the Australian Melanoma Genome Project, and a member of the Scientific Steering Committee of the International Cancer Genome Consortium. He has served on the NHMRC Health Care Committee (2012-2015), and co-chaired a NHMRC Research Translation Faculty Steering Group.

He has contributed strongly to the establishment, development and leveraging of the data and tissue resources of the Melanoma Institute Australia, and these are now supporting a wide variety of applied and translational genomics studies of biomarkers and molecular targets. His principal impacts on practice to date have been in establishing the framework for genetic risk assessment in familial melanoma internationally and the banning of commercial sunbeds in Australia. He led the chapter on high-risk individuals for the current NHMRC/CCA Clinical Practice Guidelines on Melanoma.

Role

In the Centre of Research Excellence in Melanoma Prof Mann is co-leader of the CRE Core 1: Identifying and managing people at high risk of developing melanoma.

View Profile
   

   

Professor Richard Scolyer OA

BMedSci, MBBS, MD FRCPA FRCPath FAHMS

Prof Scolyer is Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney; Co Medical Director, Melanoma Institute Australia; and Conjoint Professor, The University of Sydney. Richard studied medicine at the University of Tasmania. After completing clinical training in Australia and overseas, he undertook pathology training at the Canberra Hospital and at the Royal Prince Alfred Hospital leading to Fellowship of the Royal College of Pathologists of Australasia. He provides a clinical consultation service for the diagnosis of difficult pigmented lesions and receives more than 2000 cases for opinion from Australasia and beyond annually.

Research Interests

Professor Scolyer effectively integrates his clinical practice with leading an award winning translational melanoma research laboratory. His record includes co-authoring more than 770 peer reviewed publications, books and/or book chapters including in prestigious journals such as the New England Journal of Medicine, Lancet, Nature, Cell, Nature Genetics, Lancet Oncology, Journal of Clinical Oncology, Journal of the National Cancer Institute and Cancer Discovery with >53,760 citations and a h-index of 114 (Google Scholar as at 18.11.2021). Richard has presented on more than 390 occasions at conferences throughout the world. In June 2021, he was appointed Officer of the Order of Australia (AO) for distinguished service to medicine, particularly in the field of melanoma and skin cancer, and to national and international professional organisations by The Governor-General of the Commonwealth of Australia. In 2020, he received the Cancer Institute NSW Premier's Award – Outstanding Cancer Researcher of the Year, the Royal College of Pathologists of Australasia (RCPA) Distinguished Fellow Award 2020, The University of Sydney’s 2020 Alumni Award for International Achievement and Clarivate Web of Science Group “Highly Cited Researcher 2020”. He has received the NSW Premier's Award for Outstanding Cancer Research in 2009, 2012, 2013, 2014, 2016, 2017, 2018AND 2020, Thomson Reuters 2015 Citation Award in the Clinical Medicine category, the 2018 William O. Russell/Joanne Vandenberge Hill Award for Lifetime Achievement in Anatomical Pathology, MD Anderson Cancer Center, Research Australia’s 2018 GSK Award for Research Excellence and the 2019 American Society of Dermatopathology’s Elson B Helwig Award for excellence in dermatopathology.

His publications have received most highly cited awards on 5 other occasions. According to Thomson Reuters ISI Web of Knowledge, Richard is the highest ever published scientist in the world in the field of melanoma pathology and he also has the highest H index in this field. The Fame Report (2011) published by Medical Experts International (www.medexpert.com) ranked him the 6th leading melanoma expert in any field or discipline worldwide and the highest ranked melanoma pathologist worldwide. In September 2021, he was ranked the world's 7th leading melanoma expert in any field or discipline and the world's leading melanoma pathologist (http://expertscape.com/ex/melanoma).

Richard is an expert member of the World Health Organisation (WHO) Blue Books Editorial Board for the 5th edition of the WHO Classification of Skin Tumours series and was an editor of the 4th Edition of the World Health Organisation Classification of Tumours Skin Tumours volume in which he was the responsible editor for 3 of the 6 sections and authored/co-authored more than 30 chapters. He is also Vice Chair of the Melanoma Expert Panel of the American Joint Committee on Cancer (AJCC) for the 8th edition of AJCC Cancer Staging System, co-leads the Australian Melanoma Genome Project (part of the International Cancer Genome Consortium) (Nature 2017), was lead pathologist for the NIH funded The Cancer Genome Atlas (TCGA) Melanoma Project (Cell, 2015), chairs the Melanoma Expert Panel for the International Collaboration on Cancer Reporting, and lead pathologist/member of the overseeing Management Committee, Multidisciplinary Working Party and Author for the Australian Melanoma Clinical Practice Guidelines and a lead author of the College of American Pathologists Melanoma Reporting protocol.

He is also an editorial board member of the American Journal of Surgical Pathology, Modern Pathology and Histopathology and several other international journals and Senior Associate Editor of Pathology. Richard is a Past President of the Australasian Division of the International Academy of Pathology and is the current International Vice President representing Australasia on the International Academy of Pathology International Council. In 2019, Richard was the RCPA visiting Professor/Lecturer to Asia. Together with other MIA colleagues, Richard has been chief investigator on 3 consecutive 5 year NHMRC program grants and has received multiple personal Fellowships from the NHMRC and CINSW. He has also been an investigator/advisor on multiple phase 1, 2 and 3 clinical trials and a frequently sought-after advisor to industry.

Role

In the Centre of Research Excellence in Melanoma Prof Scolyer is executive committee member and co lead Core 2

View Sydney.edu Profile
View Melanoma.org Profile
 

   

Jeffrey Braithwaite

PhD, FAIM, FCHSM, FFPHRCP, FAcSS, Hon FRACMA, FAHMS

Professor Braithwaite is Founding Director of the Australian Institute of Health Innovation, Director of the Centre for Healthcare Resilience and Implementation Science, and Professor of Health Systems Research, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.

Research Interests

Professor Braithwaite is a leading health services and systems researcher with an international reputation for his work investigating and contributing to systems improvement and implementation science. He has particular expertise in the culture and structure of acute settings, leadership, management and change in health sector organisations, quality and safety in healthcare, accreditation and surveying processes in international context and the restructuring of health services. He is the recipient as at 2018 of career research funding of over $110.7 million spread over 76 grants; total new research funding and grants in the last five years amounts to over $66.6million; more than 80% of this grant funding is category one, peer-reviewed, chiefly ARC and NHMRC funding.

He has appointments at six other universities internationally; is a board member and President Elect of the International Society for Quality in Health Care (ISQua) and consultant to the World Health Organisation (WHO). Professor Braithwaite is well known for bringing management and leadership concepts and evidence into the clinical arena and he has published extensively (more than 450 refereed contributions, and 900 total publications).

Role

In the Centre of Research Excellence in Melanoma Prof Braithwaite is working across all cores, but primarily CRE Core 2: Leading the development of skills in implementation science across the CRE, Sentinel node biopsy study.

View Profile
   

   

Professor John Kelly

AM, MD, MBBS, FACD

Founder of the Victorian Melanoma Service, The Alfred Hospital, Melbourne, Australia

Professor John Kelly founded one of Australia's largest multidisciplinary treatment services for melanoma, the Victorian Melanoma Service, at the Alfred hospital in 1994 and remained it's Director till 2018. He trained as a dermatologist in Melbourne and undertook his Doctorate at the Melanoma Clinic, University of California, San Francisco, on the subject of melanoma diagnosis and management.

Research Interests

Major areas of research have been in the area of melanocytic naevi, clinical techniques for the early detection of melanoma, atypical presentations of melanoma and aggressive primary melanoma. The over-arching theme has been to reduce melanoma deaths by facilitating early detection. He has pursued each topic with a series of research projects that have contributed important findings of clinical significance.

Professor Kelly has served on the board of the Australia and New Zealand Melanoma Trials Group, and is a member of the Executive Steering Committee and contributing author for the wiki-based Australian Clinical Practice Guidelines for the Diagnosis and Management of Melanoma 2017.

Role

In the Centre of Research Excellence in Melanoma Prof Kelly contributes to CRE Core 1: Identifying and managing people at high risk of developing melanoma.

View Profile
   

   

Rachael Morton

MScMed(Clin Epi)(Hons), PhD

Professor Morton is Director of Health Economics and Health Technology Assessment, Robinson Fellow, and Deputy Director of the NHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney. Professor Morton is President of the Health Services Research Association of Australia and New Zealand (HSRAANZ), and faculty member of the Melanoma Institute Australia (MIA). She is Executive member of the Melanoma Clinical Outcomes Registry (MelCOR). Professor Morton holds an NHMRC Investigator grant for embedding economics into melanoma research.  In 2019 she received a Distinguished Investigator Award in Health Services Research.

Research Interests

Professor Morton has an international reputation in the economic evaluation of melanoma diagnosis, treatment and monitoring. She leads within-trial and modelled cost-effectiveness analyses to inform policy decision making on the basis of patient-centred and economic outcomes.

Her current projects alongside randomised trials include evaluation of genomic information for melanoma prevention; melanoma surveillance photography; adjuvant immunotherapy for stage III patients; whole brain radiotherapy for treatment of melanoma brain metastases; and evaluation of a psychoeducational intervention to prevent fear of cancer recurrence. She leads a program of research into the costs and benefits of CT and PET/CT monitoring, and the incorporation of patient reported outcomes measures (PROMs) to guide melanoma clinical care.

Prof Morton served on the board of the Australia and New Zealand Melanoma Trials Group (ANZMTG) for 9 years, and prior to this managed the MIA Clinical Trials Unit. She is a Board Director for the Australian Clinical Trials Alliance (ACTA) and leads the Cancer Council Australia chapter on diagnostic tests and follow-up for the Clinical Practice Guidelines on Melanoma.

Role

In the Centre of Research Excellence in Melanoma, Prof Morton is the leader of the CRE Core 4: Health Economics and Policy stream of research.

View Profile
   

   

Andrew Spillane

MD FRACS B Med Sci BMBS GAID

Professor of Surgical Oncology at The University of Sydney, Northern Clinical School.

Research Interests

Andrew's current research interests investigate issues around quality assurance in surgery, safe introduction of new surgical techniques and promoting clinical trial involvement by surgeons. He is heavily involved in clinical and translational research on aspects of melanoma and breast cancer. He is one of the leaders on the international primary melanoma width of margins study MelMART-2 that aims to determine the most appropriate surgical margins to maximise health outcomes whilst minimising morbidity.

He is CIA for the EAGLE FM clinical trial, which aims to define a the appropriate management of metastatic melanoma in the groin lymph nodes. He is a lead author and committee member for the new Cancer Council Australia Melanoma Guidelines. He has authored about 130 peer reviewed publications and co-authored 4 book chapters. He lectures and teaches junior doctors and students at the University of Sydney's, Northern Clinical School.

Role

In the Centre of Research Excellence in Melanoma Andrew is co-leader of Core 2 - The patient with curable, early stage melanoma. He is involved in the evaluation and broader implementation of sentinel node biopsy for accurately staging melanoma patients at the time of diagnosis of their early stage melanoma.

View Profile
   

   

Robyn Saw

FRACS, MS, MBBS

Associate Professor Saw is Head of Department, Melanoma and Surgical Oncology, RPAH; A/Prof, Discipline of Surgery, USyd; Clinical Academic and General Surgeon, Department of Melanoma and Surgical Oncology, RPAH; and, Faculty Member Melanoma Institute Australia (MIA).

Research Interests

Robyn Saw is a Surgical Oncologist with MIA and has a specific interest in the surgical and psycho-social management of melanoma and skin cancer. She leads major research projects on surgical trials, quality of life and survivorship. She has a strong focus on consumer engagement, coordinating the development, text and layout of an early-stage melanoma booklet and stage III melanoma patient information packs, and supervising the dissemination of the packs Australia-wide. She is passionate about educating students, clinicians, and patients and has been invited numerous times to speak to GPs and other clinicians about surgery and lymphoedema in melanoma. 

Role

In the Centre of Research Excellence in Melanoma Prof Saw will be assisting in the development of Core 2 (optimising management of early stage melanoma) and Core 3 projects.

View Profile
   

   

Professor Michael A Henderson

MBBS, BMedSc, MD, FRACS

Is the deputy director division of cancer surgery at the Peter MacCallum Cancer Centre in Melbourne. His undergraduate education was at the University of Melbourne and surgical training at St Vincent's Melbourne. This was followed by a Surgical Oncology Fellowship at the University of Texas, MD Anderson Cancer Centre in Houston. His surgical practice is limited to surgical oncology and predominantly the management of patients with cutaneous malignancy. Currently he is head of the multidisciplinary Melanoma and Skin Service at the Peter MacCallum Cancer Centre.

Research interests

Prof Henderson has had a long-standing interest in clinical and translational research. currently he is the lead for a number of multicentre studies at the Peter MacCallum Cancer Centre including Multicentre Selective Lymphadenectomy Trial 2 (MSLT2), Melanoma Margins of Excision Trial (MELMART). He is a participant in the Melbourne Melanoma Project which contributed to the recent update of the American Joint Commission on Cancer Melanoma Staging System (version 8). Currently he is co-supervising 3 higher degree students with colleagues from the research division at the Peter MacCallum Cancer Centre. He has published over 100 papers in the scientific literature and contributed chapters to 15 textbooks. He is on the working party of the Australian Cancer Society Guidelines for the Management Of Cutaneous Melanoma. Current clinical research interests include management of elderly patients with melanoma particularly the very elderly (more than 85 years of age), subungual melanoma, isolated infusion for in-transit metastasis and surveillance of patients with early stage melanoma. He was the lead investigator for the ANZMTG-TROG international multicentre randomised trial of adjuvant radiotherapy after lymphadenectomy which led to practice changing refinement of the role of adjuvant radiation. Further evaluation of results from this trial is ongoing including a detailed prospect of evaluation of the morbidity of lymphadenectomy. Currently he is the national lead investigator for the proposed ANZMTG International randomised trial of 1 cm versus 2 cm margins for melanomas > 2 mm in thickness.

Role

In the Centre of Research Excellence in Melanoma Professor Henderson will work across cores, but primarily CRE Core 2: with his colleagues in Victoria and at the Peter MacCallum Cancer Centre he will work to support the aims of the CRE specifically focusing on surgical aspects of the management of early melanoma.

View Profile
   

   

Professor Jean Yang

PHD

Professor in Statistics, School of Mathematics and Statistics, University of Sydney Theme Leader for Integrative System and Modelling | Charles Perkins Centre

Research Interests

Professor Jean Yang is an applied statistician with expertise in statistical bioinformatics. She was awarded the 2015 Moran Medal in statistics from the Australian Academy of Science in recognition of her work on developing methods for molecular data arising in cutting edge biomedical research. Her research stands at the interface between medicine and methodology development and has centered on the development of methods and the application of statistics to problems in -omics and biomedical research. In particular, her focus is on developing methods for integrating omics and clinical data to answer a variety of scientific questions. As a statistician who works in: statistical bioinformatics; applied statistics; statistical machine learning; complex data analytics and integrative analysis of omics data.

She enjoys research in a collaborative environment, working closely with scientific investigators from diverse backgrounds.

Role

In the Centre of Research Excellence in Melanoma Prof Yang will be working on Core 2: Identify biomarkers for patient with curable, early stage melanoma Statistical and bioinformatics expertise

View Profile